Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;106(11):1782-7.
doi: 10.1111/j.1464-410X.2010.09260.x.

Expression of E-series prostaglandin (EP) receptors and urodynamic effects of an EP4 receptor antagonist on cyclophosphamide-induced overactive bladder in rats

Yao-Chi Chuang  1 , Naoki Yoshimura, Chao-Cheng Huang, Moya Wu, Pradeep Tyagi, Michael B Chancellor
Affiliations

Expression of E-series prostaglandin (EP) receptors and urodynamic effects of an EP4 receptor antagonist on cyclophosphamide-induced overactive bladder in rats

Yao-Chi Chuang et al. BJU Int. 2010 Dec.

Abstract

Objective: To investigate the expression of four subtypes of E-series prostaglandin (EP(1) -EP(4) ) receptors and the urodynamic effects of an EP(4) receptor antagonist (AH23848) in cyclophosphamide (CYP)-induced overactive bladder (OAB) in rats, as intravesical prostaglandin E(2) (PGE(2) ) induces OAB via activation of EP receptors and sensitization of afferent nerves.

Materials and methods: Experimental and control rats were injected with CYP (200 mg/kg, intraperitoneally) or saline, respectively. Continuous cystometrograms (CMGs) were performed 48 h after CYP or saline injection under urethane anaesthesia. AH23848 was given intravenously at doses of 0.01 and 0.1 mg/kg. The bladder was then harvested for histology. Some bladders were harvested for analysis of EP receptors expression by Western blotting without a CMG study. CMG variables (baseline pressure; intercontraction interval [ICI], pressure threshold [PT], contraction amplitude) and histological changes were measured.

Results: CYP-induced up-regulation of EP(4) receptor (100% increase) accompanied by detrusor overactivity (ICI 70.5% decrease; PT, 67.7% increase). However, CYP down-regulated EP(1) receptor expression (51.9% decrease), but had no significant effects on the EP(2) and EP(3) receptors. AH23848 significantly extended the ICI in CYP-treated rats but it had no effects on other urodynamic variables or in control rats.

Conclusions: Modulation of EP receptors plays a role in CYP-induced OAB. Antagonists to the EP(4) receptor may be a new target for treatment of patients with OAB.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

Yao-Chi Chuang is a consultant and investigator for Allergen and Pfizer, Naoki Yoshimara is a consultant for Astellas, Pradeep Tyagi is a consultant for Lipella, and Michael B. Chancellor is a consultant for Pfizer, Astellas and Allergen.

Figures

FIG. 1
FIG. 1
A, Gross view, on day 3, CYP significantly induced swelling and haemorrhage of bladder (left) compared with the control rat (right). B, Western blotting for detecting EP receptors expression in the bladder of saline- (right) and CYP- (left) treated rats. CYP induced up-regulation of EP4 receptor accompanied by down-regulation of EP1 receptor. However, CYP had no significant effects on EP2 and EP3 receptors.
FIG. 2
FIG. 2
Representative traces of in vivo continuous CMGs in urethane-anaesthetized rats. CMG was performed in a control rat (A) with a normal voiding pattern and in a rat with CYP-induced OAB (B) before and after i.v. administration of AH23848 (0.01 and 0.1 mg/kg; i.v).
FIG. 3
FIG. 3
Photomicrographs of bladder sections. Control rat with intact urothelium (A,B) and rare EP4 immunostaining (C); CYP-induced inflammatory cells accumulation, oedematous change, haemorrhage of urothelium (D,E) and up-regulation of EP4 expression (F) at urothelium (arrow), inflammatory cells (white arrow head), and macrophage (black arrow head). A, D ×40; B, C, E, F ×200.
See this image and copyright information in PMC

References

    1. Andersson KE, Wein AJ. Pharmacology of lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004;56:581–631. - PubMed
    1. Lee T, Andersson KE, Streng T, Hedlund P. Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats – effects of bladder outlet obstruction and intravesical PGE2. Neurourol Urodyn. 2008;27 :88–95. - PubMed
    1. Lee T, Hedlund P, Newgreen D, Andersson KE. Urodynamic effects of a novel EP(1) receptor antagonist in normal rats and rats with bladder outlet obstruction. J Urol. 2007;177:1562–7. - PubMed
    1. Schussler B. Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women. A urodynamic study. Urol Res. 1990;18:349–52. - PubMed
    1. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006;175:1773–6. - PubMed

Publication types

MeSH terms

LinkOut - more resources